Clinical trials: High Risk Cardiovascular Disease, open to volunteers
High Risk Cardiovascular Disease, Hypertension
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
The purpose of this study is to evaluate whether zilebesiran versus placebo reduces the risk of cardiovascular (CV) death, nonfatal myocardial infarction (MI), nonfatal stroke, or heart failure (HF) events.
- Conditions
- High Risk Cardiovascular Disease, Hypertension, High Cardiovascular Risk
- Trial name
- ZENITH (NCT07181109)
- Testing
- Zilebesiran
- Where
- 1,190 sites in United States, Argentina and 33 more
- Volunteers
- 11,000 people
- Sponsor
- Alnylam Pharmaceuticals
Hypertensive Disorders of Pregnancy, Postpartum Hypertension
Cardiometabolic Risk in Pregnancy and Postpartum
The goal of this study is to evaluate changes in blood pressure and early cardiovascular risk markers and to determine whether a postpartum education intervention can improve cardiovascular risk monitoring among pregnant women in…
- Conditions
- Hypertensive Disorders of Pregnancy, Postpartum Hypertension, Cardiovascular Disease Risk, High Blood Pressure
- Trial name
- NCT07420465
- Testing
- Postpartum Cardiovascular Disease (CVD) Risk Reduction Program, Enhanced Postpartum Care
- Where
- Ghana
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Forgive Avorgbedor
Coronary Disease, Heart Diseases
Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO IV-EPIC 38)
This international, multicenter, open-label, randomized clinical trial evaluates the safety and efficacy of single antiplatelet therapy (SAPT) compared to dual antiplatelet therapy (DAPT) in elderly or high bleeding risk patients…
- Conditions
- Coronary Disease, Heart Diseases, Cardiovascular Diseases, Myocardial Ischemia
- Trial name
- PIV-EPIC (NCT06535568)
- Testing
- Drug-coated balloon, Single antiplatelet therapy (SAPT), Dual antiplatelet therapy (DAPT)
- Where
- Italy
- Volunteers
- 576 people
- Sponsor
- Fondazione Ricerca e Innovazione Cardiovascolare ETS
Healthy Elderly Individuals With High LDL-cholesterol or Risk of Cardiovascular Disease
Low- and Moderate-intensity Statin and Clinical Outcome of Primary Prevention in Individuals Aged >70 Years: the SCOPE-70 RCT Study
One of the most effective drug in the primary prevention of cardiovascular disease is statins. The protective effects of statin on developement of cardiovascular disease has been demonstrated in elderly individuals.
- Trial name
- NCT03770312
- Testing
- Low intensity statin, Moderate intensity statin
- Where
- South Korea
- Volunteers
- 724 people, healthy volunteers welcome
- Sponsor
- Yonsei University